pfizer glp-1 pipeline The first participants have been dosed in VESPER-6 and SOLIS-1, part of 20+ study starts planned across Pfizer's obesity in 2026. Learn more about our pipeline Argus Turns Bullish on Pfizer
Description
It stimulates insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon release, and slows gastric emptying
Its dual-action mechanism helps improve insulin secretion, reduce glucagon, and promote feelings of fullness, which supports weight loss and overall metabolic health
This sets up a double edged effect where you can burn more calories while youre eating less
K., Kaur, K
(2005) The cytoplasmic domain close to the transmembrane region of the glucagon-like peptide-1 receptor contains sequence elements that regulate agonist-dependent internalisation
